Mayo Clinic researchers have created a new blood test that is better able to detect mesothelioma. The result could be earlier diagnoses. It could also lead to new options for targeted therapies. The test works by finding complex DNA patterns that are common in mesothelioma cells. The new approach is[…]
Mesothelioma
Keytruda and Chemotherapy Approved for the Treatment of Mesothelioma
A new first line treatment was approved by the U.S. Food and Drug Administration for the treatment of pleural mesothelioma that cannot be removed by surgery. The approval is specifically for Keytruda alongside pemetrexed and platinum chemotherapy. The approval follows the promising results in phases 2 and 3 of the[…]
Study of ISM6331 in Participants With Advanced/Metastatic Malignant Mesothelioma or Other Solid Tumors
This is a Phase 1, open-label, multicenter, FIH study to evaluate the safety, tolerability, recommended Phase 2 dose (RP2D), PK/PD, and preliminary anti-tumor activity of ISM6331 in participants with advanced or metastatic malignant mesothelioma or other solid tumors. The study consists of two parts, a dose escalation part (Part 1) and a dose selection optimization part (Part 2).
CAR-T Cell Therapy for Mesothelioma
Mesothelioma is a rare, yet aggressive cancer mainly caused by asbestos exposure. There are very limited options for treatment. This is especially true for elderly patients. Conventional therapies might not be the best option due to the person’s age and other health problems. Chimeric antigen receptor (CAR) T cell therapy[…]
Sintilimab, Bevacizumab, Pemetrexed, and Cisplatin for Unresectable MPeM
To explore the efficacy and safety of sintilimab, bevacizumab combined with pemetrexed and cisplatin in the treatment of malignant peritoneal mesothelioma, and to explore the biomarkers related to efficacy or safety.
New Preclinical and Clinical Approaches to Mesothelioma
This study protocol involves the coordination between UO1 (IRCCS San Raffaele Hospital) and UO2 (Istituto Nazionale Tumori di Napoli – IRCCS G. Pascale) to explore the role of HMGB1 and CXCR4 in cancer treatment and metastasis. UO1 focuses on the role of HMGB1 in inflammation, mesothelioma progression, and tissue repair, as well as developing, in future, possible HMGB1 inhibitors for cancer therapy. UO2 specializes in CXCR4’s role in cancer, developing CXCR4 antagonists, and tracking CXCR4-dependent metastasis. The hypothesis is that targeting HMGB1 and CXCR4 pathways will inhibit tumor progression and metastasis, enhancing anti-tumor immunity and improving therapeutic outcomes in cancer.
Using Precision Cut Tumor Slices to Advance Mesothelioma Treatment
Malignant pleural mesothelioma is a cancer mainly caused by asbestos exposure that is very deadly. Research continues to be done on the cancer, giving hope to patients and their families. One tool in the fight against mesothelioma is ex-vivo models using precision cut tumor slices. A new article looks at[…]
Surgery is Beneficial for Mesothelioma Patients
Pleural mesothelioma is a cancer mainly caused by asbestos exposure. It is a cancer of the pleura, which is a lining of the lungs. The outlook for the disease is poor, with a typical survival time after diagnosis being 9 to 20 months. The overall five-year survival rate is five[…]
Artificial Intelligence and Robotics Improving Mesothelioma Care
Patient care is improving thanks to artificial intelligence and robotics. One country leading the charge in using technology for healthcare is Vietnam. A study from the Cureus Journal of Medical Sciences looks at AI and robotics improving in Vietnam and how they can help mesothelioma patients in the future. AI[…]
Changes to Staging System for Mesothelioma
Malignant pleural mesothelioma is a rare cancer associated with asbestos exposure. Two very important aspects of treating mesothelioma are classification and staging. They are important because they guide treatment and predict outcomes. One system to classify cancers is the TNM system which was created by the IASLC. It classifies cancers[…]
